Furthermore, Keech et al. (2017) state that at 2-days post treatment with doxorubicin and cytarabine, a particular subset of Mφs (CD11b–F4/80+CD169+VCAM1+) persists within these AML mice. This evidence concerns the gene SIGLEC1 and acute myeloid leukemia.